Current Report Filing (8-k)
January 05 2015 - 8:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
January 5, 2015
Date of Report (Date of Earliest
Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425
Abrams, Ville St- Laurent, Quebec, Canada |
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx to Present at the 8th Annual OneMedForum
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INTELGENX TECHNOLOGIES CORP.
|
|
|
|
|
Dated: January 5, 2015 |
By: /s/ Paul A.
Simmons
|
|
Paul A. Simmons |
|
Chief Financial Officer |
Exhibit 99.1
IntelGenx to Present at the
8thAnnual OneMedForum
Saint Laurent, Quebec - January 5, 2015 Saint Laurent,
Quebec--IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced
that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will
present at the 8th Annual OneMedForum to be held Monday, January 12,
2015 at the San Francisco Marriott Marquis. IntelGenx presentation will take
place January 12, 2015 at 10:40 A.M. Pacific Time.
Institutional investors that wish to request a meeting with
IntelGenx should contact The Cockrell Group.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery system to
provide zero-order release of active drugs in the gastrointestinal tract.
IntelGenx has also developed novel delivery technologies for the rapid delivery
of pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx' development pipeline includes
products for the treatment of indications such as severe depression,
hypertension, erectile dysfunction, migraine, insomnia, CNS indications,
idiopathic pulmonary fibrosis, oncology and pain, as well as animal health
products. More information is available about the company at
www.intelgenx.com.
Investor Contact:
COCKRELL GROUP
T: 877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Company Contact:
Paul A. Simmons
Chief Financial Officer
IntelGenx
Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Sep 2023 to Sep 2024